articleGastroenterologyJul 18, 2008Closed access

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

WJWilliam J. SandbornBGBrian G. FeaganRNRichard N. FedorakESEllen ScherlMRMark R. Fleisher

WinnMed · Mayo Clinic · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

745
total citations
FWCI
29.41
Percentile
100%
References
38
Citations per year

Authors

9

Topics & keywords

Topics
Keywords
  • Ustekinumab
  • Crohn's disease
  • Medicine
  • Monoclonal antibody
  • Randomized controlled trial
  • Monoclonal
  • Internal medicine
  • Gastroenterology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.